Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients.
Launch of ARDS emerging therapies, such as Traumakine (Faron Pharmaceuticals) Bio-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys), Solnatide (Apeptico Forschung und Entwicklung GmbH), and PB1046 (PhaseBio Pharmaceuticals) shall further create a positive impact on the market. Interferon-beta-1a—also known as Traumakine; FP-1201-lyo; MR11A8; FP-1201; Recombinant Human IFN Beta-1a—is under development by Faron Pharmaceuticals as its lead drug candidate. It is a lyophilized powder form of recombinant human.
IFN beta-1a reconstituted in water for injection. It is administered intravenously, and targets the Interferon-beta receptor 1, activating its action. In January 2018, Faron Pharmaceuticals received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine, for the treatment of ARDS. The drug is in phase III clinical developmental trial for the patients with ARDS. BioMarck Pharmaceuticals is developing its lead compound Bio-11006 under the phase II stage of development for the treatment of Adult Respiratory Distress Syndrome (ARDS).
Biomarck’s Bio-11006 is a novel, highly soluble, patented, 10 amino acid peptides. It acts as a MARCKS (Myristoylated alanine-rich C kinase substrate) protein inhibitor and is being developed to specifically target the MARCKS protein to inhibit cancer cell division and movement. Furthermore, it is a water-soluble, stable aerosolized anti-MARCKS peptide inhalation solution that involves aerosolized delivery of either the active drug or placebo by the “Aeroneb Pro nebulizer.”
MultiStem—also known as AMI MultiStem; HLCM 051 and PF-05285401—is a patented regenerative product which can promote tissue repair and healing in a variety of ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage and restore immune system balance. MultiStem is under development by Athersys and is currently in the phase II stage for the treatment of Acute Respiratory Distress Syndrome. Currently, the US FDA granted Fast Track designation to Athersys for its clinical program evaluating MultiStem cell therapy for the treatment of ARDS.
Solnatide (AP301; synonym to TNF-derived TIP-peptide) under development by Apeptico Forschung und Entwicklung GmbH is a synthetic molecule whose structure bases on the lectin-like domain of the Human Tumor Necrosis Factor α. The AP301 peptide is water-soluble and can be administered into the lung by oral inhalation. The drug is conducting phase II clinical developmental trial in patients with ARDS. PB1046, a novel, subcutaneously-injected vasoactive intestinal peptide (VIP) analogue, is a recombinant fusion protein composed of VIP and PhaseBio’s proprietary elastin-like polypeptide (ELP) biopolymer. PhaseBio recently initiated VANGARD, a clinical trial to evaluate.
PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and ARDS. Based on feedback from the FDA, PhaseBio believes that a positive, clearly interpretable and clinically meaningful result from this clinical trial may enable the submission of a Biologics License Application.
- Traumakine: Faron Pharmaceuticals
- Bio-11006: BioMarck Pharmaceuticals
- MultiStem: Athersys
- Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
- Ultomiris (ravulizumab-cwvz): Alexion Pharma
- Soliris (eculizumab): Alexion Pharma
Scope of the report
- The Acute Respiratory Distress Syndrome (ARDS) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Acute Respiratory Distress Syndrome (ARDS) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Acute Respiratory Distress Syndrome (ARDS) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Acute Respiratory Distress Syndrome (ARDS) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Acute Respiratory Distress Syndrome (ARDS).
1. Report Introduction
2. Acute Respiratory Distress Syndrome (ARDS)
2.3. Acute Respiratory Distress Syndrome (ARDS) Symptoms
2.6. Acute Respiratory Distress Syndrome (ARDS) Diagnosis
2.6.1. Diagnostic Guidelines
3. Acute Respiratory Distress Syndrome (ARDS) Current Treatment Patterns
3.1. Acute Respiratory Distress Syndrome (ARDS) Treatment Guidelines
4. Acute Respiratory Distress Syndrome (ARDS) – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Acute Respiratory Distress Syndrome (ARDS) companies collaborations, Licensing, Acquisition -Deal Value Trends
18.104.22.168. Assessment Summary
4.1.2. Acute Respiratory Distress Syndrome (ARDS) Collaboration Deals
22.214.171.124. Company-Company Collaborations (Licensing / Partnering) Analysis
126.96.36.199. Company-University Collaborations (Licensing / Partnering) Analysis
188.8.131.52. Acute Respiratory Distress Syndrome (ARDS) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
184.108.40.206. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
220.127.116.11. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
18.104.22.168. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
22.214.171.124. Assessment by Stage and MOA
5.1.6. Assessment by Target
126.96.36.199. Assessment by Stage and Target
6. Acute Respiratory Distress Syndrome (ARDS) Late Stage Products (Phase-III)
7. Acute Respiratory Distress Syndrome (ARDS) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Respiratory Distress Syndrome (ARDS) Discontinued Products
13. Acute Respiratory Distress Syndrome (ARDS) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
188.8.131.52. Product Overview
184.108.40.206. Mechanism of action
13.1.2. Research and Development
220.127.116.11. Clinical Studies
13.1.3. Product Development Activities
18.104.22.168. Patent Detail
13.1.4. Tabulated Product Summary
22.214.171.124. General Description Table
Detailed information in the report?
14. Acute Respiratory Distress Syndrome (ARDS) Key Companies
15. Acute Respiratory Distress Syndrome (ARDS) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Acute Respiratory Distress Syndrome (ARDS) Unmet Needs
18. Acute Respiratory Distress Syndrome (ARDS) Future Perspectives
19. Acute Respiratory Distress Syndrome (ARDS) Analyst Review
21. Report Methodology